Members of Dicot's board and management strengthen their shareholding
Press release: Uppsala, June 13, 2022. The company announces that members in the board and management are increasing their shareholding in the company.Dicot is developing a new potency drug that aims to be the first choice for the treatment of erectile dysfunction and premature ejaculation. The company announces today that members in the board and management are increasing their shareholding in the company. Purchase of shares, including exercise of warrants in the ongoing warrant round, series TO 3, means a total increase of holding for these members of board and management corresponding